

# 速利清 注射液

## CEREBROLYSIN Ampoules

衛署藥輸字第18737號

速利清注射液是經由管制的水解作用 controlled hydrolysis 自腦蛋白中取得，這種水溶液含有多種氨基酸——呈現於「氨基酸的原型」內之氨基酸，其相互定量的關係，以及由於水解作用的平衡發展，促成這些氨基酸和低分子縮氨酸的結合(就像其他化學反應一樣)，由於這些縮氨酸類和多量縮氨酸類沒有蛋白質的特性，因此不會有過敏的反應。

### 【成分】

Each ml contains: Cerebrolysin Concentrate 215.2mg

Alanine . . . . .	3.00mg	Methionine . . . . .	0.50mg
Arginine . . . . .	0.25mg	Phenylalanine . . . . .	2.00mg
Aspartic Acid . . . . .	3.00mg	Proline . . . . .	1.60mg
Cystine . . . . .	0.01mg	Serine . . . . .	0.30mg
Glutamic Acid . . . . .	4.50mg	Threonine . . . . .	0.30mg
Glycine . . . . .	1.50mg	Tryptophan . . . . .	0.50mg
Histidine . . . . .	1.30mg	Tyrosine . . . . .	0.24mg
Isoleucine . . . . .	2.00mg	Valine . . . . .	2.00mg
Leucine . . . . .	6.00mg	sodium Hydroxide 4N q.s. (pH 7.1)	
Lysine . . . . .	5.80mg	Water for injection q.s.	

### 【適應症】

不能攝取適當食物之患者之補助治療劑，蛋白質之消化吸收機能及合成利用障礙，嚴重創傷、火傷，骨折時蛋白質之補給，蛋白質攝取減少，營養失調症。

### 【用法用量】

治療初期每天2公撮的速利清作肌肉或靜脈的注射，然後治療間隔加長至兩或三天。

較輕的症狀每一治療過程需10~15針，較重的症狀則視需要可加長至數個治療過程。

高劑量使用5公撮或10公撮安瓿裝：

每天5-40公撮緩慢的靜脈注射或點滴注射。根據病況每一治療過程10至15針，如需要可連續數個治療過程。

本藥限由醫師使用。

### 【副作用】

注射速度太快時，會有輕微灼熱感，極少有惡寒或體溫上升之過敏反應。

### 【禁忌】

嚴重腎功能不全者。

### 【包裝】

2公撮：每盒10、50等安瓿裝。

5公撮：每盒1、5、10、30、50等安瓿裝。

10公撮：每盒1、5、50等安瓿裝。

## EVER Neuro Pharma GmbH

Mondseestraße 11, AT-4866 Unterach AM ATTERSEE, Austria

製造廠：

EBEWE Pharma Ges.m.b.H Nfg. KG

Mondseestraße 11, A-4866 Unterach AM ATTERSEE, Austria

藥商：

美吾華股份有限公司

台北市復興北路167號5樓 電話：(02) 2713-1569

Important information. Read carefully!

# Cerebrolysin®

For the treatment of disturbance of cerebral functions.

## Composition

Cerebrolysin, as a protein-free hydrolysate in aqueous solution, contains approx. 85% unbound amino acids including all the essential ones as well as approx. 15% bound amino acids in the form of low-molecular peptides. By virtue of the controlled breakdown of organspecific brain proteins it is possible to maintain the amino acids at a constant ratio to each other, with 1ml of Cerebrolysin corresponding to 1g of brain protein in terms of nitrogen content.

## Properties and effectiveness

The effectiveness of Cerebrolysin has been substantiated in numerous animal experiments and clinical trials. Cerebrolysin favourably influences protein synthesis and the respiratory chain of neurons while simultaneously stimulating the complex production of hormones. This can be inferred from the rapid cerebral development of chicks.

This is also demonstrated by experimental studies in which Cerebrolysin protects the central nervous system from noxious substances. Prior treatment of rats with Cerebrolysin induces enhanced resistance to anoxia. In these experiments a dosage-dependent effect on the nucleic acid concentration in the brain occurs.

A pronounced acceleration in maturation in the brain of several-day-old rats was demonstrated by electro-optical means, and adult rats exhibited enhanced learning ability in labyrinth tests, both after administration of Cerebrolysin.

Glucose transport processes at the blood-brain barrier improve at a markedly faster rate in Cerebrolysin-treated subjects as compared to a control group.

Abundant literature exists on therapeutic experience with Cerebrolysin. Of particular significance is a study involving an extensive number of subjects distributed among 9 different disease groups in which the effectiveness of Cerebrolysin could be established through the use of 11 psychological tests subjected to variance analysis.

In patients experiencing therapeutic hypoglycemic coma a pronounced arousal effect was observed after administration of Cerebrolysin with a correlative normalization of the EEG.

Cerebrolysin is also suitable as an adjuvant in electroshock therapy, as it has been shown to ensure more rapid recovery from amnesic disturbances.

Intractable endogenous depressions responded to antidepressant therapy following a course in Cerebrolysin therapy. The use of Cerebrolysin is often advantageous in conjunction with antiepileptic therapy. Literature on Cerebrolysin is documented in the detailed physician's prospectus.

## Indications

Cerebrovascular decompensation

Disturbed functions secondary to apoplexia, cranial surgery, and severe cerebral infections.

Organic brain syndrome.

Disturbances in concentration and memory.

Nervous exhaustion and failure symptoms.

Mild forms of infantile cerebral retardation.

Complaints following cerebral concussion or contusion.

As supportive therapy in cases of endogenous depression and epilepsy.

## Side-effects

Cerebrolysin is generally well tolerated. If injected too rapidly, it can cause a moderate heat sensation. In extremely rare cases a hypersensitivity reaction manifested in chills or a slight increase in body temperature has occurred, the cause of which is most probably to be found in the hyperresponsiveness of the patient. In no case to date has the undesirable effect persisted or proved threatening for the patient.

## Contraindications

Cerebrolysin is contraindicated in cases of severely disturbed renal functions. Caution is advisable in cases of demonstrated allergic diathesis.

## Dosage and administration

Cerebrolysin is available in 1ml, 5ml and 10ml ampoules.

It is recommended to carry out the series of injections in accordance with a course of treatment, the length of therapy and the individual doses being dependent on the age and weight of the patient and the severity of the illness.

Up to 2ml of Cerebrolysin can be injected subcutaneously, up to 5ml intramuscularly, and up to 10ml intravenously. In addition, an infusion containing 10ml to maximum 30ml diluted in approx 250ml of physiological saline is recommended, which should be given slowly enough so that the length of the infusion is approximately 60-120 minutes.

A serial course of treatment should comprise 10 to 20 injections of infusions, depending on the severity of the case.

In severe cases, especially those involving cerebrovascular decompensation, 10-30ml diluted in 250ml of physiologic saline is administered as an infusion. In the case of daily administration a series consists of 8-10 infusions. Cerebrolysin can also be combined with dextrans (eg Rheomacrodex), vitamins, and any required cardiac or circulatory drugs. In mild cases or to ensure success following high-dosage Cerebrolysin therapy series of 10 to 20 injections im (sc and iv also possible) of 1 to 5ml are given initially daily and later 2 to 3 times weekly. Cerebrolysin injection series can be repeated several times in accordance with the clinical picture until further improvement is no longer achieved.

## Presentation and packs

Original packs with 10 and 50 ampoules of 2ml

1, 5, 10, 30 and 50 ampoules of 5ml

1, 5 and 50 ampoules of 10ml

Keep in a safe place out of the reach of children.

## EBEWE Pharma Ges.m.b.H. Nfg.KG

Mondseestraße 11

A-4866 Unterach am Attersee

Austria